AT-003 is an investigational, novel drug being developed for the treatment of Diabetic Retinopathy. AT-003 is part of Applied Therapeutics’ Aldose Reductase Inhibitor (ARI) franchise. The drug inhibits the enzyme Aldose Reductase, which plays a well-established role in the pathogenesis of various conditions, including Diabetic Retinopathy.